Global /United States /Healthcare /Drug Manufacturers - General /CNTB

Connect Biopharma Holdings Ltd.

CNTB

• NASDAQ: CNTB • Delayed

2.53USD 5.4%

As of 13 June 2026, Connect Biopharma Holdings Ltd. has a market cap of $143.0M USD, ranking #23174 globally and #3677 in the United States. It ranks #2090 in the Healthcare sector, and #752 in the Drug Manufacturers - General industry.

Global Rank

23174

Country Rank

3677

Sector Rank

2090

Industry Rank

752

Key Stats

Market Cap

$143.0MUSD

Enterprise Value

$92.28MUSD

Revenue (TTM)

$64.0KUSD

EBITDA (TTM)

-$57.37MUSD

Net Income (TTM)

-$55.48MUSD

PS Ratio

2124.0

PB Ratio

3.2

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Barry Quart open_in_new

Employees

Founded

2012

IPO

19 Mar 2021

Website

connectbiopharm.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
5.4%	-1.9%	-26%	2.8%	66%	-9.6%	155%	93%	-88%

News

CNTB Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	CNTB Connect Biopharma Holdings Ltd ordinary shares ISIN: KYG235491019 Shares Out.: Shares Outstanding: 62.964M¹ Shares Float: 15.446M² TV: TradingView: NASDAQ: CNTB SA: Stock Analysis: NASDAQ: CNTB YF: Yahoo Finance: CNTB GF: Google Finance: NASDAQ: CNTB NQ: NASDAQ: CNTB BA: Barron's: CNTB MS: Morningstar: XNAS: CNTB	2.53 USD	TV: TradingView: NASDAQ: CNTB SA: Stock Analysis: NASDAQ: CNTB YF: Yahoo Finance: CNTB GF: Google Finance: NASDAQ: CNTB NQ: NASDAQ: CNTB BA: Barron's: CNTB MS: Morningstar: XNAS: CNTB

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Connect Biopharma Holdings Ltd.

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company’s lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 533K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 383K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 252K%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 192K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 104K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 82K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 225K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 202K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 192K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 127K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 77K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 76K%	14.6	United Kingdom

chevron_leftBack